Sorrento Therapeutics Announces the Appointment of Martina

Sorrento Therapeutics Announces the Appointment of Martina Molsbergen as Vice
President, Business Development

  PR Newswire

  SAN DIEGO, Oct. 27

SAN DIEGO, Oct. 27 /PRNewswire/ -- Sorrento Therapeutics, Inc. announced today
that Martina Molsbergen has joined the Company as Vice President, Business
Development. Ms. Molsbergen will focus her efforts on all aspects of business
development, including forming alliances based on Sorrento Therapeutics' human
monoclonal antibody libraries and technologies.

Ms. Molsbergen is a proven biopharmaceutical business development executive
and has negotiated dozens of licensing agreements, collaborations and
alliances during her career. Prior to joining Sorrento Therapeutics, Inc., she
held similar positions with Crucell NV, where she was responsible for
commercializing the PER.C6 manufacturing technology platform, which is based
on a fully human cell line for the expression of therapeutic antibodies and
other proteins; and with BioWa, Inc., a novel antibody engineering platform
company. BioWa, Inc. is a subsidiary of Kyowa Hakko Kirin Co., Ltd.

Dr. Antonius Schuh, Chairman and CEO of Sorrento Therapeutics, commented,
"There has been a growing demand from the pharmaceutical and biotechnology
industries for antibody-based technologies. Martina brings forth skill sets
necessary to capture the value of our human antibody library platform. Her
expertise and in-depth knowledge of our industry will be a most valuable asset
to Sorrento Therapeutics as we expand our technology platform and product
pipeline activities."

About Sorrento Therapeutics, Inc.

Sorrento Therapeutics, Inc. is a development-stage biopharmaceutical company
focused on applying its proprietary technology platform for the discovery and
development of human therapeutic antibodies for the treatment of a variety of
disease conditions, including cancer, inflammation, metabolic disease and
infectious disease. The Company seeks to construct an antibody library
containing fully human antibodies and designed to facilitate the rapid
identification and isolation of highly specific, antibody therapeutic product
candidates that are fully human and that bind to disease targets appropriate
for antibody therapy.

This press release contains "forward-looking statements," as that term is
defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
including statements regarding expectations, beliefs or intentions regarding
our business, technologies and products strategies or prospects. Actual
results may differ from those projected due to a number of risks and
uncertainties, including, but not limited to, the possibility that some or all
of the pending matters and transactions being considered by the Company and
its parent, QuikByte Software, Inc., may not proceed as contemplated, and by
all other matters specified in QuikByte's filings with the Securities and
Exchange Commission, as well as risks inherent in funding, developing and
obtaining regulatory approvals of new, commercially-viable and competitive
products and product candidates. These statements are made based upon current
expectations that are subject to risk and uncertainty and information
available to QuikByte as of the date of this press release. QuikByte does not
undertake to update forward-looking statements in this press release to
reflect actual results, changes in assumptions or changes in other factors
affecting such forward-looking information. Assumptions and other information
that could cause results to differ from those set forth in the forward-looking
information can be found in QuikByte's filings with the Securities and
Exchange Commission, including its most recent periodic report. We intend that
all forward-looking statements be subject to the safe-harbor provisions of the

For more information about Sorrento Therapeutics, Inc., visit its web site at

SOURCE Sorrento Therapeutics, Inc.

Contact: Antonius Schuh, Ph.D. , Sorrento Therapeutics, Inc., +1-858-210-3703
Press spacebar to pause and continue. Press esc to stop.